(VIANEWS) – Iamgold Corporation Ordinary Shares (IAG), Ligand Pharmaceuticals Incorporated (LGND), Capital Bancorp (CBNK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Iamgold Corporation Ordinary Shares (IAG)
76.8% sales growth and 5.86% return on equity
IAMGOLD Corporation, through its subsidiaries, explores, develops, and operates gold mining properties in North America, South America, and West Africa. The company owns interests in the Rosebel mine located in Suriname, South America; the Essakane mine situated in Burkina Faso and Boto gold project located in Senegal, West Africa; and Westwood mine, covers an area of 1,925 hectare and located in Quebec and the Côté gold project, which covers an area of 586 square kilometer located in Ontario, Canada. Its exploration and development projects include the Pitangui project in Brazil; the Karita project located in Guinea; the Diakha-Siribaya project situated in Mali; and the Nelligan and Monster Lake projects located in Quebec, Canada. IAMGOLD Corporation was incorporated in 1990 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Iamgold Corporation Ordinary Shares has a trailing twelve months EPS of $0.24.
PE Ratio
Iamgold Corporation Ordinary Shares has a trailing twelve months price to earnings ratio of 22.29. Meaning, the purchaser of the share is investing $22.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.86%.
Moving Average
Iamgold Corporation Ordinary Shares’s worth is way above its 50-day moving average of $4.46 and way higher than its 200-day moving average of $3.46.
Yearly Top and Bottom Value
Iamgold Corporation Ordinary Shares’s stock is valued at $5.35 at 11:22 EST, under its 52-week high of $5.38 and way higher than its 52-week low of $1.99.
2. Ligand Pharmaceuticals Incorporated (LGND)
49.9% sales growth and 5.85% return on equity
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Earnings Per Share
As for profitability, Ligand Pharmaceuticals Incorporated has a trailing twelve months EPS of $2.33.
PE Ratio
Ligand Pharmaceuticals Incorporated has a trailing twelve months price to earnings ratio of 45.07. Meaning, the purchaser of the share is investing $45.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.85%.
Yearly Top and Bottom Value
Ligand Pharmaceuticals Incorporated’s stock is valued at $105.01 at 11:22 EST, below its 52-week high of $112.13 and way higher than its 52-week low of $49.24.
Moving Average
Ligand Pharmaceuticals Incorporated’s value is above its 50-day moving average of $102.50 and way above its 200-day moving average of $82.39.
3. Capital Bancorp (CBNK)
33.8% sales growth and 13.29% return on equity
Capital Bancorp, Inc. operates as the bank holding company for Capital Bank, N.A. that provides various banking products and services to businesses, not-for-profit associations, and entrepreneurs in the United States. It operates through Commercial Banking, Capital Bank Home Loans, and OpenSky segments. The company offers a range of deposit products and services, including checking and savings, time, interest bearing demand, and money market accounts, as well as certificates of deposit; and credit cards. It originates residential mortgages and offers residential and commercial real estate, construction, and commercial business loans, as well as other consumer loans, such as term loans, car loans, and boat loans to small to medium-sized businesses, professionals, real estate investors, and small residential builders and individuals. It operates through four commercial bank branches, four mortgage offices, and one loan production office. The company was founded in 1974 and is headquartered in Rockville, Maryland.
Earnings Per Share
As for profitability, Capital Bancorp has a trailing twelve months EPS of $2.41.
PE Ratio
Capital Bancorp has a trailing twelve months price to earnings ratio of 10.49. Meaning, the purchaser of the share is investing $10.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.29%.
Volume
Today’s last reported volume for Capital Bancorp is 11425 which is 54.9% below its average volume of 25337.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.2%, now sitting on 157.49M for the twelve trailing months.
Moving Average
Capital Bancorp’s value is above its 50-day moving average of $24.13 and way higher than its 200-day moving average of $21.85.
Yearly Top and Bottom Value
Capital Bancorp’s stock is valued at $25.27 at 11:22 EST, under its 52-week high of $26.20 and way above its 52-week low of $15.00.
4. Impinj (PI)
27.5% sales growth and 16.08% return on equity
Impinj, Inc. operates a cloud connectivity platform in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Its platform, which comprises multiple product families, wirelessly connects individual items and delivers data about the connected items to business and consumer applications. The company's platform comprises endpoint ICs, a miniature radios-on-a-chip that attaches to a host item and includes a number to identify the item. Its platform also consists of systems products that comprise reader ICs, readers, and gateways to wirelessly provide power to and communicate bidirectionally with endpoint ICs on host items, as well as to read, write, authenticate, and engage the endpoint ICs on those items; and software and algorithms that enables its partners to deliver use cases, such as retail self-checkout and loss prevention, and warehouse pallet and carton tracking to end-users. The company primarily serves retail, supply chain and logistics, aviation, automotive, healthcare, industrial and manufacturing, sports, food, datacenter, travel, banking, and linen and uniform tracking sectors through distributors, system integrators, value-added resellers, and software solution partners. Impinj, Inc. was incorporated in 2000 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Impinj has a trailing twelve months EPS of $0.28.
PE Ratio
Impinj has a trailing twelve months price to earnings ratio of 777.96. Meaning, the purchaser of the share is investing $777.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.08%.
Sales Growth
Impinj’s sales growth is 42.9% for the present quarter and 27.5% for the next.
